



Inhibición preferencial JAK1: Filgotinib and upadacitinib

Inhibición no selectiva: Tofacitinib

Schwartz DM et al. Nat Rev Drug Discov. 2017; 16: 843-862  
 Salas A et al. Nat Rev Gastroenterol Hepatol. 2020; 17:323-337  
 Gran AH et al. Front. Immunol. 2021; 13:12:690477  
 Quintos-Cardama A et al. Nat Rev Drug Discov. 2011; 10(2):127-40

